CTOs on the Move

Q32 Bio

www.q32bio.com

 
Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.q32bio.com
  • 830 Winter Street
    Waltham, MA USA 02451
  • Phone: 781.999.0232

Executives

Name Title Contact Details
Saul Fink
Chief Technology Officer Profile

Funding

Q32 Bio raised $46M on 05/27/2020
Q32 Bio raised $60M on 10/29/2020

Similar Companies

Janssen Research and Development

Janssen Research and Development is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Antibacterial Resistance Leadership Group (ARLG)

ARLG addresses antibacterial resistance through innovative clinical trial design, unique access to clinically well-characterized bacteria, and opportunities for early-stage investigators.

AmbioPharm

AmbioPharm is a Beech Island, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ChemDiv

ChemDiv is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atomwise

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.